|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,006 DKK | +0.30% |
|
+1.79% | +44.05% |
| 06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 06-28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
COPENHAGEN (Reuters) - Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.
($1 = 6.9791 Danish crowns)
(Reporting by Louise Breusch Rasmussen, editing by Essi Lehto)
| 1st Jan change | Capi. | |
|---|---|---|
| +44.05% | 641B | |
| +55.32% | 815B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +2.04% | 224B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
NOVO NORDISK A/S 
